Cytocares Inc

This early study is testing the safety of a new drug called CC312 in adults with severe autoimmune diseases that have not improved with standard treatments. The drug works by engaging the body's own immune T cells to attack harmful B cells, using a mechanism similar to some advan…

This is the first human study of an experimental drug called CC312 for people with moderate-to-severe lupus. The main goal is to check the safety and side effects in 32 participants, and see how the body processes the drug. Researchers will also look for early signs that it might…

This is a first-in-human study to find a safe dose of an experimental drug called CC312 for adults with certain B-cell blood cancers that have come back or stopped responding to other therapies. The main goal is to check the drug's safety and how the body processes it in about 44…

This is a very early study to check the safety and initial effects of an experimental drug called CC312. It is for adults with severe, relapsed forms of lupus, myositis, or scleroderma that have not improved with standard treatments. The main goal is to find a safe dose and see h…